{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:17:16Z","timestamp":1789906636140,"version":"4.0.1"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Generalized myasthenia gravis (gMG) is a rare, chronic, autoimmune disorder with a substantial disease burden. Oral glucocorticoids (GCs) are one of the common early-line treatments used globally, but there are growing concerns regarding risks associated with GC adverse effects, which can have serious medical consequences. In Japan, an important gMG treatment goal is minimal disease manifestation with a low target GC dose (\u22645\u202fmg\/day) to minimize GC exposure. This study aimed to assess gMG treatment patterns in Japan, with a focus on GC exposure and incident comorbidities associated with long-term GC use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a retrospective, observational database study of patient data from the Medical Data Vision (MDV) database (2008\u20132022) in Japan. Adults (aged \u226518\u202fyears) with \u22652 gMG diagnosis records were considered. First gMG diagnosis (ocular MG excluded) between 2018 and 2021 was considered the index date. All available follow-up was considered if the patient had \u22651 activity in the database annually after the index date.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 9,687 patients with gMG (mean age: 65\u202fyears; 56% female; follow-up period: 3.2\u202fyears) included in the study, 3,696 (38.2%) were newly diagnosed (2018 onwards) and 5,991 (61.8%) were previously diagnosed (before 2018). Acetylcholinesterase inhibitor (AChEi) and GC monotherapy were the most common initial therapies after index, and most patients were treated with combinations of AChEi, GC, and\/or nonsteroidal immunosuppressive therapies (NSISTs). The average daily GC dose was 8.5\u202fmg\/day (newly diagnosed: 10.6\u202fmg\/day; previously diagnosed: 7.5\u202fmg\/day). The target daily dose of 5\u202fmg\/day was exceeded by 70% of GC-treated patients, and 26% exceeded 10\u202fmg\/day (newly diagnosed: 35%; previously diagnosed: 21%). Compared to patients with no GC exposure, GC use was dose-dependently associated with osteoporosis, thrombosis, diabetes, and hyperlipidemia\/hypercholesterolemia, even at GC doses \u22645\u202fmg\/day.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Most patients were treated with AChEi, GC, or NSIST monotherapy or combination therapies and received GCs exceeding 5\u202fmg\/day, which was associated with developing several GC-associated comorbidities in a dose-dependent manner. To achieve treatment goals, patients with gMG may benefit from additional treatment approaches to reduce GC usage.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2025.1625457","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T11:44:46Z","timestamp":1760096686000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Treatment patterns and impact of glucocorticoids on health outcomes in generalized myasthenia gravis: a retrospective observational study based on the Medical Data Vision database in Japan"],"prefix":"10.3389","volume":"16","author":[{"given":"Hirofumi","family":"Teranishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Challa","family":"Yachendra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori P.","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Blein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/CND.0000000000000377","article-title":"Current and upcoming treatment modalities in myasthenia gravis","volume":"23","author":"Beladakere Ramaswamy","year":"2021","journal-title":"J Clin Neuromuscul Dis"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","article-title":"Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals","volume":"82","author":"Menon","year":"2022","journal-title":"Drugs"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J Clin Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s40120-024-00617-6","article-title":"Myasthenia gravis disease burden and its impact on satisfaction with life: a qualitative survey of patients' perspectives in Japan","volume":"13","author":"Kawaguchi","year":"2024","journal-title":"Neurol Ther"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e068104","DOI":"10.1136\/bmjopen-2022-068104","article-title":"Patient-reported impact of myasthenia gravis in the real world: findings from a digital observational survey-based study (Myrealworld Mg)","volume":"13","author":"Berrih-Aknin","year":"2023","journal-title":"BMJ Open"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e066445","DOI":"10.1136\/bmjopen-2022-066445","article-title":"Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study Myrealworld-Mg","volume":"13","author":"Dewilde","year":"2023","journal-title":"BMJ Open"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e013278","DOI":"10.1136\/bmjopen-2016-013278","article-title":"Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study","volume":"7","author":"Nagane","year":"2017","journal-title":"BMJ Open"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"102266","DOI":"10.1016\/j.coi.2022.102266","article-title":"The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention","volume":"80","author":"Miller","year":"2023","journal-title":"Curr Opin Immunol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1339167","DOI":"10.3389\/fneur.2024.1339167","article-title":"Epidemiology of myasthenia gravis in the United States","volume":"15","author":"Ye","year":"2024","journal-title":"Front Neurol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1159\/000539577","article-title":"Prevalence, incidence, and mortality of myasthenia gravis and Myasthenic syndromes: a systematic review","author":"Sciancalepore","year":"2024","journal-title":"Neuroepidemiology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e0274161","DOI":"10.1371\/journal.pone.0274161","article-title":"Two-step Nationwide epidemiological survey of myasthenia gravis in Japan 2018","volume":"17","author":"Yoshikawa","year":"2022","journal-title":"PLoS One"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/mus.28006","article-title":"Incidence and prevalence of myasthenia gravis in the United States: a claims-based analysis","volume":"69","author":"Rodrigues","year":"2024","journal-title":"Muscle Nerve"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for Management of Myasthenia Gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for Management of Myasthenia Gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41582-023-00916-w","article-title":"Myasthenia gravis: the changing treatment landscape in the era of molecular therapies","volume":"20","author":"Iorio","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/cen3.12739","article-title":"The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert\u2013Eaton Myasthenic syndrome","volume":"14","author":"Murai","year":"2023","journal-title":"Clin Exp Neuroimmunol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"17562864231213240","DOI":"10.1177\/17562864231213240","article-title":"Guideline for the Management of Myasthenic Syndromes","volume":"16","author":"Wiendl","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3389\/fneur.2020.00868","article-title":"Reappraisal of Oral steroid therapy for myasthenia gravis","volume":"11","author":"Imai","year":"2020","journal-title":"Front Neurol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1136\/jnnp-2022-330519","article-title":"Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis","volume":"94","author":"Uzawa","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref20","year":"2025"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","article-title":"Long-term systemic corticosteroid exposure: a systematic literature review","volume":"39","author":"Rice","year":"2017","journal-title":"Clin Ther"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00774-024-01502-w","article-title":"The 2023 guidelines for the management and treatment of glucocorticoid-induced osteoporosis","volume":"42","author":"Tanaka","year":"2024","journal-title":"J Bone Miner Metab"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/mus.28111","article-title":"Would glucocorticoids be approved for clinical use if discovered today?","volume":"70","author":"Habib","year":"2024","journal-title":"Muscle Nerve"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/ard-2022-223358","article-title":"Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the Eular recommendations for the Management of Rheumatoid Arthritis","volume":"82","author":"Bergstra","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/cen3.12495","article-title":"Clinical burden and healthcare resource utilization associated with myasthenia gravis: assessments from a Japanese claims database","volume":"10","author":"Murai","year":"2019","journal-title":"Clin Exp Neuroimmunol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/cen3.12091","article-title":"Clinical features and treatment status of adult myasthenia gravis in Japan","volume":"5","author":"Murai","year":"2014","journal-title":"Clin Exp Neuroimmunol"},{"key":"ref27","article-title":"Mdv database overview","year":"2024"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jphys.2016.05.008","article-title":"Charlson comorbidities index","volume":"62","author":"Roffman","year":"2016","journal-title":"J Physiother"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"809999","DOI":"10.3389\/fneur.2021.809999","article-title":"Real-world healthcare resource utilization and cost burden assessment for adults with generalized myasthenia gravis in the United States","volume":"12","author":"Phillips","year":"2021","journal-title":"Front Neurol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e16518","DOI":"10.1111\/ene.16518","article-title":"Tracking myasthenia gravis severity over time: insights from the French health insurance claims database","volume":"32","author":"Attarian","year":"2024","journal-title":"Eur J Neurol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s13311-015-0398-y","article-title":"Current treatment, emerging translational therapies, and new therapeutic targets for autoimmune myasthenia gravis","volume":"13","author":"Guptill","year":"2016","journal-title":"Neurotherapeutics"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/mus.27791","article-title":"Treatment patterns in myasthenia gravis: a United States health claims analysis","volume":"67","author":"Mahic","year":"2023","journal-title":"Muscle Nerve"},{"key":"ref33","year":"2017"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3949\/ccjm.90a.22022","article-title":"What are the treatment options for myasthenia gravis if first-line agents fail?","volume":"90","author":"Zust","year":"2023","journal-title":"Cleve Clin J Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.jns.2022.120480","article-title":"Real-world utilization patterns of intravenous immunoglobulin in adults with generalized myasthenia gravis in the United States","volume":"443","author":"Qi","year":"2022","journal-title":"J Neurol Sci"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1259484","DOI":"10.3389\/fneur.2023.1259484","article-title":"Effectiveness of early glucocorticoids in myasthenia gravis: a retrospective cohort study","volume":"14","author":"Zhen","year":"2023","journal-title":"Front Neurol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"886625","DOI":"10.3389\/fneur.2022.886625","article-title":"Corticosteroid treatment-resistance in myasthenia gravis","volume":"13","author":"Kaminski","year":"2022","journal-title":"Front Neurol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"7","DOI":"10.11477\/mf.1416202551","article-title":"The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert-Eaton Myasthenic syndrome: an overview","volume":"76","author":"Murai","year":"2024","journal-title":"Brain Nerve"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/mus.24213","article-title":"Health-related quality-of-life and treatment targets in myasthenia gravis","volume":"50","author":"Utsugisawa","year":"2014","journal-title":"Muscle Nerve"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/mus.23398","article-title":"The Mg-Qol15 Japanese version: validation and associations with clinical factors","volume":"46","author":"Masuda","year":"2012","journal-title":"Muscle Nerve"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"e933296","DOI":"10.12659\/msm.933296","article-title":"Adverse side effects associated with corticosteroid therapy: a study in 39 patients with generalized myasthenia gravis","volume":"27","author":"Johnson","year":"2021","journal-title":"Med Sci Monit"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"120531","DOI":"10.1016\/j.jns.2022.120531","article-title":"A real-world analysis of factors associated with high healthcare resource utilization and costs in patients with myasthenia gravis receiving second-line treatment","volume":"445","author":"Ting","year":"2023","journal-title":"J Neurol Sci"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","article-title":"Treatment of myasthenia gravis","volume":"36","author":"Farmakidis","year":"2018","journal-title":"Neurol Clin"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s12883-019-1573-2","article-title":"Understanding side effects of therapy for myasthenia gravis and their impact on daily life","volume":"19","author":"Bacci","year":"2019","journal-title":"BMC Neurol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"17455057231176655","DOI":"10.1177\/17455057231176655","article-title":"An overview of the management of osteoporosis in the aging female population","volume":"19","author":"Amin","year":"2023","journal-title":"Womens Health (Lond)"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cen3.12731","article-title":"Japan Mg registry: chronological surveys over 10\u202fyears","volume":"14","author":"Suzuki","year":"2023","journal-title":"Clin Exp Neuroimmunol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1625457\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T11:44:47Z","timestamp":1760096687000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1625457\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":46,"alternative-id":["10.3389\/fneur.2025.1625457"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1625457","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"article-number":"1625457"}}